Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Multiple Sclerosis: Modulation of Toll-Like Receptor (TLR) Expression by Interferon-β Includes Upregulation of TLR7 in Plasmacytoid Dendritic Cells.
A Complex Case of Neuro-Behçet's Disease in a Patient Previously Diagnosed with multiple Sclerosis: A Case Report.
Flupirtine as neuroprotective add-on therapy in autoimmune optic neuritis.
Parainfectious longitudinally extensive transverse myelitis associated with varicella-zoster virus.
Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages.
The possible effects of the solar and geomagnetic activity on multiple sclerosis.
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.
Associations Between Fatigue and Disability, Functional Mobility, Depression, and Quality of Life in People with Multiple Sclerosis.
Rituximab Efficiently Depletes Increased CD20-Expressing T Cells in Multiple Sclerosis Patients.
In vivo and in vitro effects of multiple sclerosis immunomodulatory therapeutics on glutamatergic excitotoxicity.
Dimethyl fumarate treatment of relapsing-remitting multiple sclerosis influences B-cell subsets.
Opinion: Focus on preclinical sex differences will not address women's and men's health disparities.
Diagnosis and treatment of hyponatraemia.
Dimethyl fumarate protection against collagen II degradation.
Optimal combination of FLAIR and T2-weighted MRI for improved lesion contrast in multiple sclerosis.
Women's Issues in Multiple Sclerosis.
Quality improvement in neurology: Multiple sclerosis quality measures: Executive summary.
Genpharm and Genzyme Aubagio ® agreement for the MENA region
Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS) in the Italian population.
Pediatric Multiple Sclerosis.
NF-κB transcriptional activation by TNFα requires phospholipase C, extracellular signal-regulated kinase 2 and poly(ADP-ribose) polymerase-1.
[Prevalence of multiple sclerosis in the Region of Murcia].
FDA approves Genzyme’s AUBAGIO® (teriflunomide), a once-daily, oral treatment for relapsing multiple sclerosis
Autoantigen-specific immunosuppression with tolerogenic peripheral blood cells prevents relapses in a mouse model of relapsing-remitting multiple sclerosis.
Dimethyl Fumarate and Monoethyl Fumarate Exhibit Differential Effects on KEAP1, NRF2 Activation, and Glutathione Depletion In Vitro.

Pages